Beam Therapeutics (BEAM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.18
- Estimate
- -$1.13
- Surprise
- -4.8%
- Revenue (period 2026-06-30)
- $490,000
- Score today
- 4.3/10
Revenue source: xbrl.
How the report landed
Beam Therapeutics (BEAM) reported a wider loss than forecast — diluted EPS of -$1.18 against the -$1.13 estimate (a 4.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates BEAM Sell at 4.3/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -4.8% surprise compares with a +76.3% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Pipeline: risto-cel
- Quality below floor (1.8 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -30.9%), Material insider selling (23 sells, 3.81% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $24.12
- Price target
- $45.37
- Stop
- $23.23
- Upside to target
- +88.1%
- Reward-to-risk
- 6.3:1
Risk check: RSI 28 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
BEAM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.48B
- P/E (fwd)
- -5.1
- 52-week range
- $20.23–$38.26
- Off 52-week high
- 37.0%
- RSI (14)
- 28
- Volume vs avg
- 0.64×
- Score today
- 4.3/10